StockNews.com upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) from a sell rating to a hold rating in a report released on Wednesday.
ARCT has been the subject of a number of other research reports. Wells Fargo & Company dropped their price target on Arcturus Therapeutics from $105.00 to $98.00 and set an overweight rating for the company in a research report on Wednesday, August 10th. HC Wainwright dropped their price target on Arcturus Therapeutics from $25.00 to $19.00 in a research report on Tuesday, May 10th. Brookline Capital Management restated a buy rating on shares of Arcturus Therapeutics in a research report on Wednesday, August 10th. The Goldman Sachs Group dropped their price target on Arcturus Therapeutics from $14.00 to $8.00 and set a sell rating for the company in a research report on Tuesday, May 24th. Finally, Raymond James cut Arcturus Therapeutics from a market perform rating to an underperform rating in a research report on Wednesday, August 10th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Hold and an average price target of $38.75.
Get
Arcturus Therapeutics alerts:
Arcturus Therapeutics Trading Up 2.1 %
NASDAQ:ARCT opened at $15.43 on Wednesday. The stock has a fifty day moving average price of $17.30 and a two-hundred day moving average price of $19.48. The stock has a market capitalization of $410.07 million, a price-to-earnings ratio of -2.46 and a beta of 2.74. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.14 and a current ratio of 3.14. Arcturus Therapeutics has a 1 year low of $11.70 and a 1 year high of $56.49.
Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) last released its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.90) by $1.08. The firm had revenue of $27.09 million during the quarter, compared to analysts' expectations of $3.33 million. Arcturus Therapeutics had a negative return on equity of 78.54% and a negative net
margin of 407.91%. During the same quarter in the prior year, the business posted ($2.07) earnings per share. As a group, sell-side analysts anticipate that Arcturus Therapeutics will post -6.5 earnings per share for the current fiscal year.
Institutional Trading of Arcturus Therapeutics
A number of large investors have recently made changes to their positions in ARCT. Federated Hermes Inc. boosted its stake in Arcturus Therapeutics by 1.8% in the 1st quarter. Federated Hermes Inc. now owns 3,761,900 shares of the biotechnology company's stock worth $101,421,000 after buying an additional 66,971 shares during the last quarter. State Street Corp lifted its holdings in shares of Arcturus Therapeutics by 56.5% during the 1st quarter. State Street Corp now owns 3,217,957 shares of the biotechnology company's stock valued at $86,756,000 after acquiring an additional 1,161,883 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Arcturus Therapeutics by 2.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,436,194 shares of the biotechnology company's stock worth $22,606,000 after buying an additional 34,116 shares in the last quarter. Nikko Asset Management Americas Inc. increased its position in shares of Arcturus Therapeutics by 2.4% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,436,194 shares of the biotechnology company's stock worth $17,952,000 after purchasing an additional 34,116 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Arcturus Therapeutics by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 1,153,513 shares of the biotechnology company's stock worth $31,099,000 after purchasing an additional 6,291 shares during the last quarter. Institutional investors and hedge funds own 83.55% of the company's stock.
Arcturus Therapeutics Company Profile
(Get Rating)
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
Further Reading
- Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
